MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.
Justin M. Balko(Vanderbilt University Medical Center), Randall S. Davis(University of Colorado Cancer Center), Melinda E. Sanders(Vanderbilt University), Douglas B. Johnson(Vanderbilt University Medical Center), Daniel M. Schreeder(Clearview Cancer Institute), Paula I. González-Ericsson(Breast Cancer Research Foundation), Violeta Sánchez(Vanderbilt University), Mellissa J. Nixon, Daniel Ying Wang(Vanderbilt University Medical Center), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Ju‐Young Kim(Lineage Cell Therapeutics (United States)), Roberto Salgado(Institut Jules Bordet)
Cited by 9
Related Papers
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k